849094-11-7

Upstream product

• 849094-09-3 3-cyclopropylmethylsulfanyl-2(R)-[2,2,2-trifluoro-1(S)-(4-fluoro-phenyl)-ethylamino]propan-1-ol 
• 1408001-09-1 potassium (R,Z)-3-((cyclopropylmethyl)thio)-2-((2,2,2-trifluoro-1-(4-fluorophenyl)ethylidene)-amino)propanoate 
• 655-32-3 2,2,2-trifluoro-1-(4-fluorophenyl)ethanone 
• 10213-10-2 sodium tungstate (VI) dihydrate 
• 849094-18-4 (R)-3-((cyclopropylmethyl)thio)-2-(((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)amino)propanoic acid 
• 1779-48-2 phenylphosphinic acid 
• 32503-27-8 tetra(n-butyl)ammonium hydrogensulfate 

Downstream Products

• 1408001-11-5 (3S)-N-cyclopropyl-3-((R)-3-((cyclopropylmethyl)sulfonyl)-2-(((S)-2,2,2-trifluoro-1-(4-fluorophenyl)-ethyl)amino)propanamido)-2-hydroxypentanamide 
• 1310340-58-9 (S)-N-cyclopropyl-3-((R)-3-(cyclopropylmethylsulfonyl)-2-((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethylamino)propanamido)-2-oxopentanamide 

Relevant academic research and scientific papers

CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN

The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.